Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18798809 | 0.90 | TRPV1 (0.56) | TRPV1GAAHPGDL3MBTL1HDAC1 | |
| SCHEMBL18798870 | 0.90 | TRPV1 (0.56) | TRPV1GAAHPGDL3MBTL1LMNA | |
| SCHEMBL18798901 | 0.88 | TRPV1 (0.53) | TRPV1GAAHPGDL3MBTL1LMNA | |
| SCHEMBL18798874 | 0.87 | TRPV1 (0.51) | TRPV1GAAHPGDL3MBTL1HDAC1 | |
| SCHEMBL18798805 | 0.87 | TRPV1 (0.52) | TRPV1GAAHPGDL3MBTL1HDAC1 | |
| SCHEMBL16909176 | 0.87 | GAA (0.55) | TRPV1GAAHPGDL3MBTL1HDAC1 | |
| SCHEMBL16909235 | 0.86 | TRPV1 (0.51) | TRPV1GAAHPGDL3MBTL1LMNA | |
| SCHEMBL16909197 | 0.86 | TRPV1 (0.48) | TRPV1GAAHPGDL3MBTL1LMNA | |
| SCHEMBL16909201 | 0.86 | TRPV1 (0.48) | TRPV1GAAHPGDL3MBTL1LMNA | |
| SCHEMBL16909147 | 0.86 | CTSL (0.49) | TRPV1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | HDAC5, HDAC1, HDAC3 | TRPV1 2926/4885GAA 381/4885HPGD 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.